Analysis of factors influencing the distribution of 131-I in combined treatment of Licartin with transcatheter arterial chemoembolization in primary hepatic carcinoma.

Tang, Ming; Li, Wen-Liang; Li, Jia-Yu; Lv, Juan; Chen, Fu-Kun; Zhu, Jia-Lun; Liu, Peng-Jie

Tang, Ming; Li, Wen-Liang; Li, Jia-Yu; Lv, Juan; Chen, Fu-Kun; Zhu, Jia-Lun; Liu, Peng-Jie.

Affiliation

Tang M; Department of Pathology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Li WL; Department of Pathology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Li JY; Department of Nuclear Medical, The First People's Hospital of Zhaotong City, Zhaotong, China.
Lv J; Department of Nuclear Medical, The Cancer Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Chen FK; Department of Nuclear Medical, The Cancer Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Zhu JL; Department of Nuclear Medical, The Cancer Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Liu PJ; Department of Nuclear Medical, The Cancer Hospital of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.

Front Oncol ; 12: 993948, 2022.

Article de En | MEDLINE | ID: mdl-36994225

Mots clés

131-I; Hepatocellular carcinoma; Licartin (131I Metuximab); combined treatment; transcatheter arterial chemoembolization

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Front Oncol Année: 2022 Type de document: Article Pays d'affiliation: Chine Pays de publication: Suisse

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google